Metraipolis › archive › dc_bbb194982a5f

Efficacy and safety of inotuzumab ozogamicin and its combination therapies in acute lymphoblastic leukemia: a systematic review and meta-analysis — Europe PMC PMID:41262905

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41262905
DOI
10.3389/fonc.2025.1613777
License (as archived)
solo-consultazione
Archived
2026-11-08T19:29:45.955Z
SHA-256 of the archived text
cdac27076210f88cebbba52b4de6fd7cfc5977e082170dc61e71037259743cb9
Stable URL of this page
https://metraipolis.com/documento/dc_bbb194982a5f

How to cite

Efficacy and safety of inotuzumab ozogamicin and its combination therapies in acute lymphoblastic leukemia: a systematic review and meta-analysis — Europe PMC PMID:41262905 — Europe PMC (en), https://europepmc.org/article/MED/41262905 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bbb194982a5f (Metraipolis archive dc_bbb194982a5f, sha256 cdac27076210f88cebbba52b4de6fd7cfc5977e082170dc61e71037259743cb9)
BibTeX
@misc{dcbbb194982a5f,
  title = {Efficacy and safety of inotuzumab ozogamicin and its combination therapies in acute lymphoblastic leukemia: a systematic review and meta-analysis — Europe PMC PMID:41262905},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41262905},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bbb194982a5f; sha256 cdac27076210f88cebbba52b4de6fd7cfc5977e082170dc61e71037259743cb9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41262905. Agents can read the archived copy with the MCP tool read_document.